Category Archives: Guest Post
Confessions of a New York Times Washington Correspondent – Bob Smith Pt 2/2
Bob Smith got the Watergate break-in leak before the Washington Post. But the New York Times, then as now, avoids tough political stories.
Read more...Congress Moves to Reclaim Its War Powers
Congress has roused itself from its stupor over our undeclared, or more accurately, unapproved wars. But will much change?
Read more...2:00PM Water Cooler 7/30/2021
~ Today’s (Friday’s) Water Cooler ~
Read more...Is the UK Back in Lockdown?
Another theory about the apparent decline in UK Covid cases right after Freedom Day.
Read more...Fed Up With Democrats, Thousands March to Demand Medicare for All
More voters recognize that the Democrats will do squat about expanded health coverage like Medicare for All unless they feel some heat
Read more...2:00PM Water Cooler 7/29/2021
~ Today’s Water Cooler ~
Read more...A 20-Foot Sea Wall Won’t Save Miami – But Living Structures Can
How to rescue Miami…and other coastal cities that will otherwise be largely under water.
Read more...Cuomo’s Incoherent “Come Back En Masse” Strategy Ignores Delta Dangers
Cuomo, like his Team Dem allies, insists the vaccines will allow him to stay the reopening course when Delta is throwing a big money wrench
Read more...Grassroots Fight for $15 Movement Has Won $150 Billion in Raises for Millions of Workers, Study Shows
The campaign to raise the hourly wage to $15 has been racking up successes, even if the press doesn’t much take notice.
Read more...The Infinite Loop of Empty Direct-to-Consumer Branding
Taking note of a weirdly hollow millenial-focused consumer brand type.
Read more...2:00PM Water Cooler 7/28/2021
~ Today’s Water Cooler ~
Read more...Confessions of a New York Times Washington Correspondent – Bob Smith Pt 1/2
The New York Times is impartial when convenient…which wasn’t during Watergate, My Lai, the Iraq War, and the Trump era, for instance
Read more...Links 7/28/21
Aducanumab: The Drug That Breaks Medicare?
Biogen plans to price-gouge for the barely-effective Alzheimer’s drug aducanumab to such a degree that it could bust Medicare.
Read more...